Table 2 Hematological and non-hematological adverse events
Adverse events | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
|---|---|---|---|---|
Number of cycles in which hematological adverse events were reported (n = 283) | ||||
Neutropenia | 11 (4%) | 28 (10%) | 58 (20%) | 113 (40%) |
Thrombocytopenia | 70 (25%) | 48 (17%) | 17 (6%) | 10 (4%) |
Anemia | 85 (30%) | 34 (12%) | 11 (4%) | 0 |
Febrile neutropenia | 0 | 0 | 15 (5%) | 0 |
Number of patients with hematological adverse events (n = 49) | ||||
Neutropenia | 2 (4%) | 3 (6%) | 15 (31%) | 26 (53%) |
Thrombocytopenia | 12 (24%) | 10 (20%) | 4 (8%) | 1 (2%) |
Anemia | 17 (35%) | 12 (24%) | 9 (18%) | 0 |
Febrile neutropenia | 0 | 0 | 6 (12%) | 0 |
Number of patients with non-hematological adverse events (n = 49) | ||||
Liver function abnormalities | 5 (10%) | 1 (2%) | 4 (8%) | 0 |
Infection | 2 (4%) | 6 (12%) | 8 (16%) | 0 |
Fatigue | 2 (4%) | 3 (6%) | 0 | 0 |
Vomiting | 3 (6%) | 1 (2%) | 0 | 0 |
Diarrhea | 2 (4%) | 1 (2%) | 0 | 0 |
Hypoalbuminemia | 5 (10%) | 0 | 0 | 0 |
Hypokalemia | 4 (8%) | 0 | 0 | 0 |
Heart failure | 0 | 1 (2%) | 0 | 0 |
Atrial fibrillation | 0 | 1 (2%) | 0 | 0 |
Neurological | 2 (4%) | 0 | 0 | 0 |